Evaluation of ALLERgen Specific Vaccination of DOG Allergic Patients in Swedish Practice

• Lung function assessed by Peak Expiratory Flow (PEF)
• Nasal airflow assessed by Peak Nasal Inspiratory Flow (PNIF)
• Serum levels of allergen-specific IgE to Can f 1, Can f 2, Can f 3, Can f 4, Can f 5, and Can f 6
• Symptom severity assessed using a Visual Analogue Scale (VAS)

Inclusion criteria

The subject has provided written informed consent to participate in the study.

• Age 18-50 years.
• Moderate-to-severe allergic symptoms upon exposure to dogs.
• Dog allergy confirmed by positive specific IgE.
• Considered suitable by the investigator for treatment with Alutard SQ Dog in accordance with the approved Summary of Product Characteristics (SmPC).
• Female subjects of childbearing potential must use adequate contraception.
• A negative pregnancy test must be obtained prior to enrolment.

Exclusion criteria

• Pregnancy or breastfeeding.
• Autoimmune or connective tissue disease.
• Cardiovascular disease.
• Hepatic disease.
• Renal disease.
• Malignancy.
• Upper airway disease (e.g., non-allergic sinusitis or nasal polyposis).
• Chronic obstructive or restrictive lung disease.
• Treatment with medications that may interfere with the immune response.
• Previous immunotherapy or chemotherapy.
• Significant chronic disease.
• Major metabolic disease.
• Alcohol or substance abuse.
• Mental or cognitive incapacity that may impair compliance with study procedures.
• Known or suspected hypersensitivity to the study product.
• Suspected or confirmed bacterial infection.
• Clinically relevant allergy to house dust mite.
• Current dog ownership.
• Any condition that, in the investigator's opinion, may make participation, follow-up, or study assessments inappropriate.
• Any subject considered unsuitable for enrolment according to the principles of the Declaration of Helsinki.